Clinical trial
Efficacy and Safety of Ramelteon in Subjects With Mild to Moderate Alzheimer's…
NCT00325728 · Takeda, Industry · Completed
Key facts
| NCT number | NCT00325728 |
|---|---|
| Title | Efficacy and Safety of Ramelteon in Subjects With Mild to Moderate Alzheimer's Disease |
| Official title | A Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of 8 Week Treatment of Rozerem 8 mg (QHS) in Sleep Disturbed, Mild to Moderately Severe Alzheimer's Disease Subjects |
| Lead sponsor | Takeda, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Insomnia |
| Intervention type | Drug |
| Interventions | Ramelteon, Placebo |
| Enrollment | 74 |
| Start date | Mar 21, 2006 |
| Primary completion | Aug 1, 2007 |
| Completion | Aug 20, 2007 |
| First posted | May 15, 2006 |
| Last update posted | Aug 14, 2017 |
| Countries | United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: